Recurring commercial orders

Search documents
California Nanotechnologies Announces FY2025 Results
Newsfileยท 2025-06-26 11:00
Core Insights - California Nanotechnologies Corp. reported revenues of US$6,224,738 for the fiscal year ending February 28, 2025, marking an 87% increase from the previous year [1] - The company experienced a net loss of US$158,333, a significant decline from a net income of US$381,678 in the prior fiscal year, primarily due to non-cash charges related to share purchase warrants [2] - Adjusted EBITDA for the fiscal year was US$2,558,515, a substantial increase of 121% compared to US$1,157,141 in the previous year [6][12] Financial Performance - Revenues for the fiscal quarter ended February 28, 2025, were US$1,147,522, representing a 17% increase year-over-year [6] - Gross margin for the fiscal year was 74%, an improvement from 70% in the previous year, attributed to operational efficiencies [5][12] - The company reported cash flow from operations of US$2,923,881, a dramatic increase of 2,704% compared to US$104,284 in the prior year [12] Business Strategy and Outlook - The CEO stated that the company is entering a new phase aimed at creating predictable and scalable revenues through recurring commercial orders [4] - The company has made significant investments in personnel and equipment, totaling over US$2 million in FY2025, to support future growth [8] - The company aims to diversify its revenue streams and reduce reliance on a single customer, particularly in light of reduced activity from its green steel customer [9][10] Operational Highlights - The increase in revenue was primarily driven by manufacturing services, which generated US$5,316,068, and Spark Plasma Sintering (SPS) equipment deliveries, contributing US$908,670 [4] - The company has improved its balance sheet by fully repaying borrowings from Omni-Lite Industries Canada Inc., enhancing its financial flexibility [11] - The company anticipates fluctuations in gross margin based on the mix of manufacturing services and equipment sales [5]